within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AD03_Voclosporin;
model Voclosporin 
   extends Pharmacolibrary.Drugs.ATC.L.L04AD03;

  annotation(Documentation(
    info ="<html><body><p>Voclosporin is a novel calcineurin inhibitor immunosuppressant, structurally derived from cyclosporine, and is primarily used for the treatment of lupus nephritis in adult patients. It is approved for use in multiple countries including the US (FDA, 2021).</p><h4>Pharmacokinetics</h4><p>Healthy adult volunteers (mixed sex); oral administration under fasting or fed conditions.</p><h4>References</h4><ol><li><p>van Gelder, T, et al., &amp; Huizinga, RB (2022). Voclosporin: a novel calcineurin inhibitor for the treatment of lupus nephritis. <i>Expert review of clinical pharmacology</i> 15(5) 515–529. DOI:<a href=&quot;https://doi.org/10.1080/17512433.2022.2092470&quot;>10.1080/17512433.2022.2092470</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35763288/&quot;>https://pubmed.ncbi.nlm.nih.gov/35763288</a></p></li><li><p>Heo, YA (2021). Voclosporin: First Approval. <i>Drugs</i> 81(5) 605–610. DOI:<a href=&quot;https://doi.org/10.1007/s40265-021-01488-z&quot;>10.1007/s40265-021-01488-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33788181/&quot;>https://pubmed.ncbi.nlm.nih.gov/33788181</a></p></li><li><p> (2021). Voclosporin (Lupkynis) for lupus nephritis. <i>The Medical letter on drugs and therapeutics</i> 63(1631) 134–136. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34544103/&quot;>https://pubmed.ncbi.nlm.nih.gov/34544103</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Voclosporin;
